Efficacy of Parecoxib on Patients With CRPS

Study Overview
=================
Brief Summary
-----------------
The complex regional pain syndrom is a weighty disease that often results in a lifelong disability. Mostly this disease appears unilateral after comparatively mundane fractures or operations. In early stages CRPS shows inflammatory processes. These inflammatory components can be seen as edema and vasodilatation. These inflammatory processes lead us to the hypothesis that selective COX-2-inhibitors might help patients with CRPS.

Official Title
-----------------
Efficiacy of the Selctive COX-2-inhibitor Parecoxibe on the Pathological Low Pressure Pain Threshold (PPT) of Patients With Complex Regional Pain Syndrome (CRPS)

Conditions
-----------------
Causalgia

Intervention / Treatment
-----------------
* Drug: Parecoxib
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with saved diagnosis of CRPS of the upper extremity based on the current used criteria for diagnosis plus a positiv 3-phase-sceletal-scintilgraphy, if they show pathological PPT-values in QST on the ipsilateral site (Z-values > 2 in age- and gender-based Z-transformation of the raw values)• age ≥ 18 years• Existence of an age-based normal creatinin-clearance (calculated with a defined formula) Exclusion Criteria: Important cardiovascular illness for the purpose of heart failure (NYHA II - IV), coronary heart disease (CHD), peripheral artery occlusive disease (PAOD) or unstable hypertension (values constantly over 140/90 mm Hg) Florid kidney disease Cerebral disease Neurological systemic disorder (exception: beginning polyneuropathy with normal values of the PPT on the opposite side) Lesion of the median nerve (ipsi- oder contralateral) Acute bleeding disease Known ulcer of the stomach or duodenum Inflammatory bowel disease Positive anamnesis of a gastrointestinal bleeding in the last 5 years Important hepatic dysfunction (Child- pugh > 9) Hypersensitivity to the agent or to sulfonamides Known allergy to acetylsalicylic acid, nonsteroidal antiinflammatory drugs or other selectiv cyclooxygenase-inhibitors Pregnancy and lactation period Intake of one of the following drugs (current or in the last 3 days) selective-serotonin-reuptake-inhibitor cetoconazole rifampicin phenytoin carbamazepine dexamethasone or other systemic corticoids traditional nonsteroidal antiphlogistics cyclooxygenase-inhibitors immunsupressives TNF-α-inhibitors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row|
|Drug: Placebo|NaCl i.v. two times a day, two days in an row|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Causalgia, CRPS, complex regional pain syndrome, Dynastat, Parecoxib